We specialize in targeted bioanalytical support for today’s most important therapeutic classes. Whether you’re working with small molecules, proteins or therapeutic peptides, our team delivers accurate, timely data tailored to your analyte’s unique properties and study requirements.
From discovery to GLP-regulated studies, we provide high-sensitivity LC-MS/MS analysis optimized for small molecules. Our workflows are designed to accelerate timelines without sacrificing quality — ensuring reliable, reproducible data for confident decision-making.
Key strengths include:
Veloxity offers targeted support for protein-based therapeutics, including mAbs, ADCs, nanobodies and GLP-1 receptor agonists. Our team develops and validates customized LC-MS workflows to meet the sensitivity, specificity and compliance needs of each program.
Our experience includes:
What matters most:
Veloxity builds peptide-savvy methods that anticipate the next phase, supporting a smooth transition from fit-for-purpose → GLP → clinical.
Peptides demand the speed and sensitivity of a CRO that knows their complexity. Veloxity delivers peptide-specific assay development, fit-for-purpose validation and full support for preclinical and clinical bioanalysis — helping you meet aggressive timelines and regulatory standards.
Capabilities include:
LC-MS has advanced to the point where it’s the smarter choice. Here are 3 reasons why LC-MS peptide bioanalysis is more efficient, flexible and reliable:
We also support a wide range of non-traditional and exploratory modalities. When your program doesn’t fit into a box, we build the workflow to match — delivering data that keeps development moving forward.
Introduce more specificity into your projects for greater sensitivity and better method performance. Fill out the form to download our report and learn how we can help you drastically increase the lead time for bioanalysis with our novel LC-MS/MS workflow that can be applied to all human IgG-based therapeutics.
